|Articles|April 15, 2003
- BioPharm International-04-01-2003
- Volume 16
- Issue 4
Guest Editorial: Benchmarking Biotech
Author(s)Michael E. Kamarck
by Michael Kamarck, Wyeth BioPharma
Advertisement
Articles in this issue
over 22 years ago
Virus Inactivation in the 1990s and into the 21st Centuryover 22 years ago
Getting Ready for Risk-Based GMPsover 22 years ago
GMP Issues: Breaking Groundover 22 years ago
Optimized Nutrient Additives for Fed-Batch Culturesover 22 years ago
Inside Washington: GMP Progress ReportNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
Why Product-Specific Strategies Matter in Advanced Therapy Manufacturing (Part 3)
5
